Vaccine-Preventable Disease
Q&A: How to talk to families about vaccines
NEW YORK — Vaccine hesitancy is only one factor leading to a decrease in vaccine coverage in the United States, so pediatric providers may need to try multiple strategies to improve vaccine uptake, according to Sean O’Leary, MD, MPH, FAAP.
Measles Vaccines
Prevention and Treatment
Immunology
Pathogenesis
Virology
Q&A: Will Moderna's mRNA RSV vaccine increase uptake next respiratory virus season?
In late May, the FDA announced approval of Moderna's mResvia, marking the third vaccine approved for respiratory syncytial virus and first time messenger RNA technology has been used for preventing a disease other than COVID-19.
Survey shows low RSV vaccine uptake among older adults in the US
A recent survey showed that only about one-quarter of older adults have received respiratory syncytial virus vaccinations.
Multiple RSV vaccines in late-stage development show promise in older adults
WASHINGTON — Three late-breaking studies offered a promising glimpse of respiratory syncytial virus vaccines in the pipeline for older adults — including the RSVPreF3 OA vaccine, which showed an overall vaccine efficacy of about 83%.
FDA authorizes Moderna, Pfizer’s bivalent omicron boosters for children, adolescents
The FDA has granted an emergency use authorization for booster doses of Moderna and Pfizer-BioNTech’s omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines for children and adolescents, both companies announced today.